

To: (10)(2e) /FR(10)(2e) @sanofi.com; (10)(2e) (THL)(10)(2e) @thl.fi; (10)(2e) @nivel.nl
Cc: (10)(2e) @rivm.nl; (10)(2e) @umcutrecht.nl; (10)(2e) @regionh.dk; (10)(2e) @rivm.nl; (10)(2e) @rivm.nl; (10)(2e) @rivm.nl; (10)(2e) @rivm.nl; (10)(2e) @rivm.nl; (10)(2e) @rivm.nl; (10)(2e) @rivm.nl; (10)(2e) @rivm.nl; (10)(2e) @rivm.nl
From: (10)(2e)
Sent: Mon 9/7/2020 1:54:32 PM
Subject: Re: WP2 fiche feedback
Received: Mon 9/7/2020 1:56:13 PM

Thanks (10)(2e) and (10)(2e)
 This is good news and very encouraging. I will ask (10)(2e) to include WHO Euro in the proposed AG.
 (10)(2e)

(10)(2e) (10)(2e) (10)(2e)
 (10)(2e)

Centre for Global Health,
 Usher Institute,
 The University of Edinburgh,
 (10)(2e) Medical School, Teviot Place,
 Edinburgh EH8 9AG
 United Kingdom
 Ph: +44 (0) 131 (10)(2e)
 E-mail: (10)(2e) @ed.ac.uk
 Profile (10)(2e)
 (10)(2e) Respiratory Viral Epidemiology Group (www.ed.ac.uk/usher/respiratory-viral-epidemiology)
 RVEG twitter: (10)(2e)

(10)(2e) Respiratory Syncytial Virus Consortium in Europe – RESCEU (www.resc-eu.org)

Usher Institute website: <http://www.ed.ac.uk/usher>



THE UNIVERSITY
 of EDINBURGH

Usher
 institute



Please excuse any inadvertent inconsistencies as speech recognition software has been used

From: " (10)(2e) /FR" <(10)(2e) @sanofi.com>
Date: Monday, 7 September 2020 at 14:02
To: " (10)(2e) (THL)" <(10)(2e) @thl.fi>, (10)(2e) <(10)(2e) @nivel.nl>, (10)(2e) <(10)(2e) @ed.ac.uk>
Cc: (10)(2e) <(10)(2e) @rivm.nl>, (10)(2e) <(10)(2e) @umcutrecht.nl>, (10)(2e) <(10)(2e) @regionh.dk>, (10)(2e) <(10)(2e) @rivm.nl>, (10)(2e) <(10)(2e) @rivm.nl>, (10)(2e) <(10)(2e) @rivm.nl>, (10)(2e) <(10)(2e) @rivm.nl>, (10)(2e) <(10)(2e) @rivm.nl>, (10)(2e) <(10)(2e) @rivm.nl>, (10)(2e) <(10)(2e) @rivm.nl>
Subject: RE: WP2 fiche feedback

departments.

(10)(2e) suggested that the initiatives that you mentioned are not of direct benefit to local RSV surveillance as only a small number in Europe is participating in that. The WHO RSV EQA in which EU labs would participate has been cancelled, there is no centralised RSV sequence database for sharing and online analysis of sequences. No doubt that in establishing sustainable virological / epidemiological surveillance of RSV in Europe we should line up with what WHO is doing. I know that (10)(2e) is trying to get the view of WHO Euro on this (today).

N.B. I am not speaking for our RIVM immunology / vaccinology centre ((10)(2e)), replacing (10)(2e) , which will definitely have an interest in participating in work of the other PROMISE work packages.

Best regards,

(10)(2e)

(10)(2e)

Centre for Epidemiology and Surveillance of Infectious Diseases | Centre for Infectious Disease Control
Dutch National Institute for Public Health and the Environment (RIVM)

PO Box 1 | 3720 BA Bilthoven

T +31 (10)(2e)

M +31 6 (10)(2e)

(10)(2e) @rivm.nl

<http://www.rivm.nl>

RIVM Committed to health and sustainability

From: (10)(2e) <(10)(2e)@ed.ac.uk>
Sent: woensdag 26 augustus 2020 17:30
To: (10)(2e) (THL) <(10)(2e)@thl.fi>
Cc: (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@nivel.nl>; (10)(2e) <(10)(2e)/FR <(10)(2e)@sanofi.com>; (10)(2e) <(10)(2e)@umcutrecht.nl>; (10)(2e) <(10)(2e)@regionh.dk>
Subject: WP2 fiche feedback

Dear (10)(2e)

I have reviewed WP2 fiche on sharepoint and given specific comments there. In general I think Tasks 2.3, 2.4, 2.5 and 2.7 look good. Task 2.6 needs to be fleshed out as it relates to meetings but we need clear objectives and outputs / outcomes from these. I have serious concerns regarding feasibility of T2.1 and moderate concerns re T2.2. I think T2.1 is at risk if we do not have ECDC buy in. I would rather than this focus on trying to coalesce ideas re building a broad respiratory surveillance platform as that will deal with RSV, COVID and any new pathogen. This will be a real value addition (perhaps we can learn from what is being done by USCDC in this regard)?

T2.2 is re-inventing a lot of things that have already been done. Lots of work ongoing with regard to (10)(2e) surveillance by DIVERGE ((10)(2e) / (10)(2e)), RSV Society ((10)(2e) / (10)(2e)), WHO. So we need to be seen to be making value addition to this? This task is of importance for mab so what is it that EFPIA want here?

I do not see any academic partners involved / mentioned in any of WP2 tasks (except TUCH). You could indicate some acad partners even if they will have minor involvement.

(10)(2e)

(10)(2e) (10)(2e) (10)(2e)
 (10)(2e)
 Centre for Global Health,
 Usher Institute,
 The University of Edinburgh,
 (10)(2e) Medical School, Teviot Place,

Edinburgh EH8 9AG
 United Kingdom
 Ph: +44 (0) 131 (10)(2e)
 E-mail: (10)(2e) @ed.ac.uk
 Profile (10)(2e)
 Group lead- Respiratory Viral Epidemiology Group (www.ed.ac.uk/usher/respiratory-viral-epidemiology)
 RVEG twitter- (10)(2e)

Co-ordinator- Respiratory Syncytial Virus Consortium in Europe – RESCEU (www.resc-eu.org)

Usher Institute website: <http://www.ed.ac.uk/usher>

<image001.png>

<image002.png>

<image003.jpg>

Please excuse any inadvertent inconsistencies as speech recognition software has been used

The University of Edinburgh is a charitable body, registered in Scotland, with registration number SC005336.

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.
www.rivm.nl/en Committed to health and sustainability

This message contains information that may be privileged or confidential and is the property of Nivel. It is intended exclusively for the person to whom it is addressed. If you are not the intended recipient you are not authorized to use this message or any part thereof. If you receive this message in error please notify the sender immediately and delete all copies of this message. Nivel rules out any and every liability resulting from any electronic transmission. No rights may be derived from the contents of this e-mail message. --

 Cette communication (y compris les pièces jointes) est réservée à l'usage exclusif du destinataire (des destinataires) et peut contenir des informations privilégiées, confidentielles, exemptées de divulgation selon la loi ou protégées par les droits d'auteur. Si vous n'êtes pas un destinataire, toute utilisation, divulgation, distribution, reproduction, examen ou copie (totale ou partielle) est non-autorisée et peut être illégale. Tout message électronique est susceptible d'altération et son intégrité ne peut être assurée. Sanofi Pasteur décline toute responsabilité au titre de ce message s'il a été modifié ou falsifié. Si vous n'êtes pas destinataire de ce message, merci de le détruire immédiatement et d'avertir l'expéditeur de l'erreur de distribution et de la destruction du message. Merci.
 This transmission (including any attachments) is intended solely for the use of the addressee(s) and may contain confidential information including trade secrets which are privileged, confidential, exempt from disclosure under applicable law and/or subject to copyright. If you are not an intended recipient, any use, disclosure, distribution, reproduction, review or copying (either whole or partial) is unauthorized and may be unlawful. E-mails are susceptible to alteration and their integrity cannot be guaranteed. Sanofi Pasteur shall not be liable for this e-mail if modified or falsified. If you are not the intended recipient of this e-mail, please delete it immediately from your system and notify the sender of the wrong delivery and the mail deletion. Thank you.
